secwatch.observer — SEC 8-K summary
======================================

Issuer:     Design Therapeutics, Inc. (DSGN)
CIK:        0001807120
Form:       8-K
Filed at:   2022-08-08T23:59:59+00:00
Accession:  0000950170-22-015520
Event type: earnings
Sentiment:  neutral
Materiality: 0.55
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Design Therapeutics reports Q2 net loss $15M; holds $359.4M cash; initial FA data expected Q4 2022
--------------------------------------------------------------------------------

- Net loss of $15.0M for Q2 2022; R&D expenses $11.3M; G&A expenses $4.3M.
- Cash, equivalents and securities totaled $359.4M as of June 30, 2022, providing multi-year runway.
- Initial Phase 1 single-ascending dose data for DT-216 in Friedreich ataxia expected Q4 2022.
- Clinical development for myotonic dystrophy type-1 GeneTAC program anticipated in 2023.
- Preclinical FECD program advancing; molecules showed nearly complete reduction in toxic RNA foci in vitro.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1807120/000095017022015520/0000950170-22-015520-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1807120/000095017022015520/dsgn-20220808.htm
  HTML page:      https://secwatch.observer/filing/0000950170-22-015520

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer